title: Rosiglitazone: what went wrong?
authors.affiliation: dcohen@bmj.com
authors.forename: Deborah
authors.initials: D
authors.lastname: Cohen
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000600:supply & distribution*; D000077154:Rosiglitazone; D056737:Safety-Based Drug Withdrawals; D045162:Thiazolidinediones / Q000009:adverse effects / Q000600:supply & distribution*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone